Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof

Patent metadata

Field	Value
Publication number	US-9512185-B2
Application number	US-201214123305-A
Country	US
Kind code	B2
Filing date	Jun 1, 2012
Priority date	Jun 1, 2011
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.

First claim

The invention claimed is:

1. A fusion protein comprising a fragment of CRM197 and a target protein, wherein said fragment of CRM197 enhances immunogenicity of the target protein, wherein said fragment of CRM197 consists of amino acids 1-190 of SEQ ID NO:2, and the target protein is an HEV capsid protein or an immunogenic fragment thereof or an influenza virus M2 protein or an immunogenic fragment thereof, and wherein the fragment of CRM197 is linked to the N-terminus and/or C-terminus of the target protein, optionally via a linker.

2. A polynucleotide encoding the fusion protein of claim 1 .

3. An expression vector comprising the polynucleotide of claim 2 .

4. A host cell comprising the polynucleotide of claim 2 .

5. A pharmaceutical composition or vaccine comprising the fusion protein of claim 1 and a pharmaceutically acceptable carrier and/or excipient.

6. The fusion protein of claim 1 , wherein said fragment of CRM197 is linked to the N-terminus and/or C-terminus of the target protein via a linker.

7. The fusion protein of claim 1 , wherein the fusion protein comprises SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:18.

8. The fusion protein of claim 1 , wherein the fusion protein comprises SEQ ID NO:38 or SEQ ID NO:44.

9. The fusion protein of claim 1 , wherein the immunogenic fragment of HEV capsid protein comprises HEV-239 (aa 368-606 of the HEV capsid protein), E2 (aa 394-606 of the HEV capsid protein) or E2s (aa 455-606 of the HEV capsid protein).

10. The fusion protein of claim 1 , wherein the immunogenic fragment of the influenza virus M2 protein comprises M2e (aa 1-24 of the M2 protein).

Assignees

• Li Shaowei
• Song Cuiling
• Yang Chunyan
• Gu Ying
• Luo Wenxin
• Xia Ningshao
• Univ Xiamen
• Xiamen Innovax Biotech Co Ltd

Inventors

• Li Shaowei
• Song Cuiling
• Yang Chunyan
• Gu Ying
• Luo Wenxin
• Xia Ningshao

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K39/05

  Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium {(Mycobacterium A61K39/04) · CPC title